Brand Fortibac · Manufacturer ADDICOO GROUP s.r.o.
↗ public sourceswww.addicoo.com/fortibac· 4 studies, 4 independent/mixed
Evidence · strong
The active substance is backed by 4 studies including meta-analyses; the verdict per claim below reflects what the literature actually shows, not the brochure. Strength reflects the active substance, not the brand.
What the manufacturer claims
Free
Captured from the product page, typed and attributed — the producer’s own statements, checked against the literature below.
Safety
Antibacterial effect (e.g. Clostridium sp., E. coli) that is independent of pH, controlling intestinal microflora throughout the digestive tract
Physiological
Modulates the microbiome and supports intestinal integrity, regeneration of the intestinal wall and an anti-inflammatory effect
Performance
Better animal performance
Manufacturer’s own words — not independently verified. The ledger below gives the evidence verdict for each.
Claim ↔ evidence ledger
Verdict free · receipts in Power
Each claim against the studies on the active substance, with the funding split. Open a row for the studies behind the verdict.
Claim
Verdict
Evidence & funding
SafetyAntibacterial effect (e.g. Clostridium sp., E. coli) that is independent of pH, cont…
Supported
2 studies · 100% indep
›
Read pH-independent antibacterial action (esp. Clostridium) is independently well supported for the glyceride class.
2021
Monoglyceride blend reduces mortality, improves digestibility and intestinal health in broilers under clinical necrotic enteritis challengeA monoglyceride blend reduced mortality and improved nutrient digestibility and intestinal health vs control under C. perfringens + Eimeria challenge
Microencapsulated fatty acid antimicrobial activity and prevention of C. perfringens-induced necrotic enteritis in broilersCaprylic/capric/lauric fatty acids showed in-vitro anti-C. perfringens activity and in-vivo NE control by disrupting membranes
PhysiologicalModulates the microbiome and supports intestinal integrity, regeneration of the inte…
Supported
2 studies · 100% indep
›
Read Microbiome modulation, barrier and anti-inflammatory effects are independently supported.
2021
Short and medium chain fatty acids and their derivatives in necrotic enteritis and microbial homeostasis in broilers (review)SCFA/MCFA and their α-monoglyceride derivatives control C. perfringens and support intestinal homeostasis
Buffered formic acid and a monoglyceride blend improve performance and modulate gut bacteria/immunity gene expression in broilers under NE challengeMonoglycerides of short- and medium-chain fatty acids improved performance and modulated gut microbiota and immune gene expression
Performance gains are demonstrated mainly under challenge in the class evidence; product-specific performance data are in the maker's own (unverified) dossiers.
IndependentMixedIndustryNone/undisclosed
Bottom line. Fortibac is a fatty-acid ester (glyceride) blend whose key selling point — pH-independent antibacterial action throughout the gut — is exactly what the glyceride class is known for.
Sponsored
728×90 — direct-sold creative, or a responsive Google AdSense unit when unsold
Composition
Free
● Disclosed by manufacturer
fatty-acid esters — esters of selected fatty acids (specific fatty acids not disclosed)pH-independent antibacterial gut-health actives
◆ Referenced — with resolving source
None referenced with a resolving source yet.
Evidence — on the active substance
Table free · full-text in Power
Why these studies The evidence for a proprietary product is the evidence for its active substance. These are the studies (meta-analyses first) behind the verdicts above, with funding labelled.
Year
Study & effect size
Funding
Type
Access
2021
Monoglyceride blend reduces mortality, improves digestibility and intestinal health in broilers under clinical necrotic enteritis challengeA monoglyceride blend reduced mortality and improved nutrient digestibility and intestinal health vs control under C. perfringens + Eimeria challenge
Short and medium chain fatty acids and their derivatives in necrotic enteritis and microbial homeostasis in broilers (review)SCFA/MCFA and their α-monoglyceride derivatives control C. perfringens and support intestinal homeostasis
Buffered formic acid and a monoglyceride blend improve performance and modulate gut bacteria/immunity gene expression in broilers under NE challengeMonoglycerides of short- and medium-chain fatty acids improved performance and modulated gut microbiota and immune gene expression
Microencapsulated fatty acid antimicrobial activity and prevention of C. perfringens-induced necrotic enteritis in broilersCaprylic/capric/lauric fatty acids showed in-vitro anti-C. perfringens activity and in-vivo NE control by disrupting membranes
728×90 — direct-sold creative, or a responsive Google AdSense unit when unsold
Analysis & tools
◆ Power
The working map a maker won’t give you — built only from the evidence on this page. Nothing here is marketing.
◆ Power view
Open the analyst workbench
Dose benchmark, the independent-vs-sponsored split, the pooled meta-analysis effects, the contradictions and the gaps — all derived from the studies above.
Dose: label vs effective trial range vs EU max
Independence-of-evidence breakdown
Pooled meta-analysis effect sizes
Compare · CSV / JSON · API
Dose benchmark
Label / recommendedNot stated on page
Effective in trials≈0.2-0.5% (comparable monoglyceride blends)
EU maximumGoverned by emulsifier good-practice use
Benefit is clearest in pathogen-challenged (e.g. necrotic-enteritis) conditions.
Fortibac is a fatty-acid ester (glyceride) blend whose key selling point — pH-independent antibacterial action throughout the gut — is exactly what the glyceride class is known for.
Independent broiler challenge trials and a review consistently show fatty-acid monoglycerides control Clostridium perfringens/necrotic enteritis and improve gut health and performance.
The mechanism (membrane disruption, pH-independent) is well established and distinguishes esters from free organic acids that need a low pH.
The maker does not disclose which fatty acids are used, so this assessment is at the ester/glyceride class level.
Regulatory note: fatty-acid esters are authorised as emulsifiers/sensory additives; the antibacterial gut-health benefit is a functional claim rather than a separate authorised function.
Where studies disagree: No material contradiction; effects are most pronounced under disease challenge, and the maker does not disclose which fatty acids are used, so the class evidence is the best available proxy.
Gaps: Specific fatty acids in the blend are not disclosed. Product-specific (Fortibac) performance data sit in the maker's own dossiers, not captured here. No product-specific patent captured.
Manufacturer’s stated mechanism (their words): A combination of fatty-acid esters (glycerides) that, unlike free organic acids, act independently of pH throughout the digestive tract; in their ester form they disrupt the membranes of Gram-positive and Gram-negative pathogens (e.g. Clostridium, E. coli), modulate the microbiome and support intestinal integrity and an anti-inflammatory state.
Compare & export
Put this beside alternatives on the same active substance (e.g. HMBi / other rumen-protected methionine), and take the data with you.
Sponsored
970×90 — direct-sold creative, or a responsive Google AdSense unit when unsold